Parexel teams with BioFortis to offer biological sample lifecycle management services

Parexel has launched a new offering that enables customers to manage patient biological sample assets across the supply chain, as precision medicine becomes more prominent, says VP.

Parexel and BioFortis, a Washington DC Metro area-based company that provides precision medicine technology solutions, announced the new service this week during the 9th Annual SCOPE Summit for Clinical Ops Executives, which is taking place in Orlando, FL.

Precision medicine is becoming more prominent and, with it, there is an increased use of human biological samples, which is expected to continually rise,” said Sanjay Vyas, corporate vice president and global head, Clinical Trial Supplies and Logistics, Parexel.

Additionally with the changing regulatory landscape, biopharmaceutical companies must now have full visibility into the chain of custody and consent status of human samples throughout the entire lifecycle,” Vyas told us.

The Biological Sample Lifecycle Management offering combines Parexel’s laboratory logistics and genomic medicine know-how with BioFortis’ web-based consent and sample tracking software, Labmatrix, according to the company.

The new offering will enable companies to meet the requirements of evolving regulations and guidelines, said Vyas.

Additionally, it will “quickly and seamlessly determine details such as what specific research the patient’s sample can be used for, if and how long it will be stored after the study and if it’s to be used for a purpose other than the current research,” he explained